[
  {
    "ts": null,
    "headline": "Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal",
    "summary": "Beam Therapeutics Inc. is a Strong Buy with promising trial results, a solid cash runway, and key data updates ahead. Click for this updated look at BEAM stock.",
    "url": "https://finnhub.io/api/news?id=137eb02c726267a970f68e7a3d613533944ed047fce6ae4e26a154a04a024159",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764859196,
      "headline": "Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal",
      "id": 137689461,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248796575/image_2248796575.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Beam Therapeutics Inc. is a Strong Buy with promising trial results, a solid cash runway, and key data updates ahead. Click for this updated look at BEAM stock.",
      "url": "https://finnhub.io/api/news?id=137eb02c726267a970f68e7a3d613533944ed047fce6ae4e26a154a04a024159"
    }
  },
  {
    "ts": null,
    "headline": "Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy",
    "summary": "Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth potential. Click for this CRSP update.",
    "url": "https://finnhub.io/api/news?id=0c0fd8fef65b190bf9c8395f52f646fd5a20fb1ef943bb2877d45e24b9f1f0de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764844190,
      "headline": "Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy",
      "id": 137680924,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196575232/image_2196575232.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth potential. Click for this CRSP update.",
      "url": "https://finnhub.io/api/news?id=0c0fd8fef65b190bf9c8395f52f646fd5a20fb1ef943bb2877d45e24b9f1f0de"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Under $50 We’re Skeptical Of",
    "summary": "Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.",
    "url": "https://finnhub.io/api/news?id=3b06e8466bab35d78463b3441ce77149bbb260e1a2e582c9c5e0428b8fb92289",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764822738,
      "headline": "3 Stocks Under $50 We’re Skeptical Of",
      "id": 137680242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.",
      "url": "https://finnhub.io/api/news?id=3b06e8466bab35d78463b3441ce77149bbb260e1a2e582c9c5e0428b8fb92289"
    }
  }
]